Top

Published in:

Open Access 01-09-2017 | Neurological Update

An update on migraine: current understanding and future directions

Authors: Francesca Puledda, Roberta Messina, Peter J. Goadsby

Published in: Journal of Neurology | Issue 9/2017

Abstract

Migraine is a common brain disorder with high disability rates which involves a series of abnormal neuronal networks, interacting at different levels of the central and peripheral nervous system. An increase in the interest around migraine pathophysiology has allowed researchers to unravel certain neurophysiological mechanisms and neurotransmitter involvement culminating in the recent development of novel therapies, which might substantially change the clinical approach to migraine patients. The present review will highlight the current aspects of migraine pathophysiology, covering an understanding of the complex workings of the migraine state and the brain regions responsible for them. We will further discuss the therapeutic agents which have appeared in the most recent years for migraine care, from calcitonin gene-related peptide (CGRP) receptor antagonists, gepants; through serotonin 5-HT_1F receptor agonists, ditans, and CGRP or CGRP receptor monoclonal antibodies to invasive and non-invasive neuromodulation techniques.

Global Burden of Disease Study 2013 Collaborators (2015) Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet (Lond, Engl) 386:743–800CrossRef

Goadsby PJ (2016) Bench to bedside advances in the 21st century for primary headache disorders: migraine treatments for migraine patients. Brain 139:2571–2577PubMedCrossRef

Amin FM, Asghar MS, Hougaard A, Hansen AE, Larsen VA, de Koning PJ, Larsson HB, Olesen J, Ashina M (2013) Magnetic resonance angiography of intracranial and extracranial arteries in patients with spontaneous migraine without aura: a cross-sectional study. Lancet Neurol 12:454–461PubMedCrossRef

Goadsby PJ, Holland PR, Martins-Oliveira M, Hoffmann J, Schankin C, Akerman S (2017) Pathophysiology of migraine—a disorder of sensory processing. Physiol Rev 97(2):553–622PubMedCrossRef

Charles A (2013) Migraine: a brain state. Curr Opin Neurol 26:235–239PubMedCrossRef

Ferrari MD, Klever RR, Terwindt GM, Ayata C, van den Maagdenberg AM (2015) Migraine pathophysiology: lessons from mouse models and human genetics. Lancet Neurol 14:65–80PubMedCrossRef

Messlinger K, Fischer MJ, Lennerz JK (2011) Neuropeptide effects in the trigeminal system: pathophysiology and clinical relevance in migraine. Keio J Med 60:82–89PubMedCrossRef

Ho TW, Edvinsson L, Goadsby PJ (2010) CGRP and its receptors provide new insights into migraine pathophysiology. Nat Rev Neurol 6:573–582PubMedCrossRef

Goadsby PJ, Hoskin KL (1997) The distribution of trigeminovascular afferents in the nonhuman primate brain Macaca nemestrina: a c-fos immunocytochemical study. J Anat 190(Pt 3):367–375PubMedPubMedCentralCrossRef

10.

Hoskin KL, Zagami A, Goadsby PJ (1999) Stimulation of the middle meningeal artery leads to Fos expression in the trigeminocervical nucleus: a comparative study of monkey and cat. J Anat 194:579–588PubMedPubMedCentralCrossRef

11.

Goadsby PJ, Charbit AR, Andreou AP, Akerman S, Holland PR (2009) Neurobiology of migraine. Neuroscience 161:327–341PubMedCrossRef

12.

Akerman S, Holland PR, Goadsby PJ (2011) Diencephalic and brainstem mechanisms in migraine. Nat Rev Neurosci 12:570–584PubMedCrossRef

13.

Moskowitz MA, Cutrer FM (1993) SUMATRIPTAN: a receptor-targeted treatment for migraine. Annu Rev Med 44:145–154PubMedCrossRef

14.

Markowitz S, Saito K, Moskowitz MA (1987) Neurogenically mediated leakage of plasma proteins occurs from blood vessels in dura mater but not brain. J Neurosci 7:4129–4136PubMed

15.

May A, Goadsby PJ (2001) Substance P receptor antagonists in the therapy of migraine. Expert Opinion Investig Drugs 10:1–6CrossRef

16.

Peroutka SJ (2005) Neurogenic inflammation and migraine: implications for therapeutics. Mol Interv 5:306–313CrossRef

17.

Raskin NH, Hosobuchi Y, Lamb S (1987) Headache may arise from perturbation of brain. Headache 27:416–420PubMedCrossRef

18.

Weiller C, May A, Limmroth V, Juptner M, Kaube H, Schayck RV, Coenen HH, Diener HC (1995) Brain stem activation in spontaneous human migraine attacks. Nat Med 1:658–660PubMedCrossRef

19.

Bahra A, Matharu MS, Buchel C, Frackowiak RS, Goadsby PJ (2001) Brainstem activation specific to migraine headache. Lancet 357:1016–1017PubMedCrossRef

20.

Stankewitz A, Aderjan D, Eippert F, May A (2011) Trigeminal nociceptive transmission in migraineurs predicts migraine attacks. J Neurosci 31:1937–1943PubMedCrossRef

21.

Goadsby PJ, Duckworth JW (1989) Low frequency stimulation of the locus coeruleus reduces regional cerebral blood flow in the spinalized cat. Brain Res 476:71–77PubMedCrossRef

22.

Vinogradova LV (2015) Comparative potency of sensory-induced brainstem activation to trigger spreading depression and seizures in the cortex of awake rats: implications for the pathophysiology of migraine aura. Cephalalgia 35:979–986PubMedCrossRef

23.

Borsook D, Burstein R (2012) The enigma of the dorsolateral pons as a migraine generator. Cephalalgia 32:803–812PubMedPubMedCentralCrossRef

24.

Kroger IL, May A (2015) Triptan-induced disruption of trigemino-cortical connectivity. Neurology 84:2124–2131PubMedCrossRef

25.

Goadsby PJ, Hoskin KL (1996) Inhibition of trigeminal neurons by intravenous administration of the serotonin (5HT)1B/D receptor agonist zolmitriptan (311C90): are brain stem sites therapeutic target in migraine? Pain 67:355–359PubMedCrossRef

26.

Goadsby PJ, Gundlach AL (1991) Localization of 3H-dihydroergotamine-binding sites in the cat central nervous system: relevance to migraine. Ann Neurol 29:91–94PubMedCrossRef

27.

Hoskin KL, Kaube H, Goadsby PJ (1996) Central activation of the trigeminovascular pathway in the cat is inhibited by dihydroergotamine. A c-Fos and electrophysiological study. Brain 119(Pt 1):249–256PubMedCrossRef

28.

Pozo-Rosich P, Storer RJ, Charbit AR, Goadsby PJ (2015) Periaqueductal gray calcitonin gene-related peptide modulates trigeminovascular neurons. Cephalalgia 35:1298–1307PubMedCrossRef

29.

Storer RJ, Akerman S, Goadsby PJ (2004) Calcitonin gene-related peptide (CGRP) modulates nociceptive trigeminovascular transmission in the cat. Br J Pharmacol 142:1171–1181PubMedPubMedCentralCrossRef

30.

May A, Bahra A, Buchel C, Frackowiak RS, Goadsby PJ (1998) Hypothalamic activation in cluster headache attacks. Lancet (Lond, Engl) 352:275–278CrossRef

31.

Goadsby PJ (2012) Trigeminal autonomic cephalalgias. Continuum (Minneapolis, Minn) 18:883–895

32.

May A (2005) Cluster headache: pathogenesis, diagnosis, and management. Lancet (Lond, Engl) 366:843–855CrossRef

33.

Kagan R, Kainz V, Burstein R, Noseda R (2013) Hypothalamic and basal ganglia projections to the posterior thalamus: possible role in modulation of migraine headache and photophobia. Neuroscience 248:359–368PubMedCrossRef

34.

Abdallah K, Artola A, Monconduit L, Dallel R, Luccarini P (2013) Bilateral descending hypothalamic projections to the spinal trigeminal nucleus caudalis in rats. PLoS One 8:e73022PubMedPubMedCentralCrossRef

35.

Robert C, Bourgeais L, Arreto CD, Condes-Lara M, Noseda R, Jay T, Villanueva L (2013) Paraventricular hypothalamic regulation of trigeminovascular mechanisms involved in headaches. J Neurosci 33:8827–8840PubMedCrossRef

36.

Moulton EA, Becerra L, Johnson A, Burstein R, Borsook D (2014) Altered hypothalamic functional connectivity with autonomic circuits and the locus coeruleus in migraine. PLoS One 9:e95508PubMedPubMedCentralCrossRef

37.

Denuelle M, Fabre N, Payoux P, Chollet F, Geraud G (2007) Hypothalamic activation in spontaneous migraine attacks. Headache 47:1418–1426PubMed

38.

Maniyar FH, Sprenger T, Monteith T, Schankin C, Goadsby PJ (2014) Brain activations in the premonitory phase of nitroglycerin-triggered migraine attacks. Brain 137:232–241PubMedCrossRef

39.

Schulte LH, May A (2016) The migraine generator revisited: continuous scanning of the migraine cycle over 30 days and three spontaneous attacks. Brain 139:1987–1993PubMedCrossRef

40.

Oliveira MM, Akerman S, Tavares I, Goadsby PJ (2016) Neuropeptide Y inhibits the trigeminovascular pathway through NPY Y1 receptor: implications for migraine. Pain 157:1666–1673PubMedCentralCrossRef

41.

Noseda R, Jakubowski M, Kainz V, Borsook D, Burstein R (2011) Cortical projections of functionally identified thalamic trigeminovascular neurons: implications for migraine headache and its associated symptoms. J Neurosci 31:14204–14217PubMedPubMedCentralCrossRef

42.

Noseda R, Kainz V, Borsook D, Burstein R (2014) Neurochemical pathways that converge on thalamic trigeminovascular neurons: potential substrate for modulation of migraine by sleep, food intake, stress and anxiety. PLoS One 9:e103929PubMedPubMedCentralCrossRef

43.

Messina R, Rocca MA, Colombo B, Pagani E, Falini A, Comi G, Filippi M (2015) White matter microstructure abnormalities in pediatric migraine patients. Cephalalgia 35:1278–1286PubMedCrossRef

44.

Coppola G, Tinelli E, Lepre C, Iacovelli E, Di Lorenzo C, Di Lorenzo G, Serrao M, Pauri F, Fiermonte G, Bianco F, Pierelli F (2014) Dynamic changes in thalamic microstructure of migraine without aura patients: a diffusion tensor magnetic resonance imaging study. Eur J Neurol 21:287PubMedCrossRef

45.

Magon S, May A, Stankewitz A, Goadsby PJ, Tso AR, Ashina M, Amin FM, Seifert CL, Chakravarty MM, Muller J, Sprenger T (2015) Morphological abnormalities of thalamic subnuclei in migraine: a multicenter MRI study at 3 tesla. J Neurosci 35:13800–13806PubMedCrossRef

46.

Porcaro C, Di Lorenzo G, Seri S, Pierelli F, Tecchio F, Coppola G (2016) Impaired brainstem and thalamic high-frequency oscillatory EEG activity in migraine between attacks. Cephalalgia

47.

Hodkinson DJ, Wilcox SL, Veggeberg R, Noseda R, Burstein R, Borsook D, Becerra L (2016) Increased amplitude of thalamocortical low-frequency oscillations in patients with migraine. J Neurosci 36:8026–8036PubMedPubMedCentralCrossRef

48.

Afridi SK, Matharu MS, Lee L, Kaube H, Friston KJ, Frackowiak RS, Goadsby PJ (2005) A PET study exploring the laterality of brainstem activation in migraine using glyceryl trinitrate. Brain 128:932–939PubMedCrossRef

49.

Afridi SK, Giffin NJ, Kaube H, Friston KJ, Ward NS, Frackowiak RS, Goadsby PJ (2005) A positron emission tomographic study in spontaneous migraine. Arch Neurol 62:1270–1275PubMedCrossRef

50.

Noseda R, Kainz V, Jakubowski M, Gooley JJ, Saper CB, Digre K, Burstein R (2010) A neural mechanism for exacerbation of headache by light. Nat Neurosci 13:239–245PubMedPubMedCentralCrossRef

51.

Burstein R, Jakubowski M, Garcia-Nicas E, Kainz V, Bajwa Z, Hargreaves R, Becerra L, Borsook D (2010) Thalamic sensitization transforms localized pain into widespread allodynia. Ann Neurol 68:81–91PubMedPubMedCentralCrossRef

52.

Shields KG, Goadsby PJ (2005) Propranolol modulates trigeminovascular responses in thalamic ventroposteromedial nucleus: a role in migraine? Brain 128:86–97PubMedCrossRef

53.

Tepe N, Filiz A, Dilekoz E, Akcali D, Sara Y, Charles A, Bolay H (2015) The thalamic reticular nucleus is activated by cortical spreading depression in freely moving rats: prevention by acute valproate administration. Eur J Neurosci 41:120–128PubMedCrossRef

54.

Andreou AP, Shields KG, Goadsby PJ (2010) GABA and valproate modulate trigeminovascular nociceptive transmission in the thalamus. Neurobiol Dis 37:314–323PubMedCrossRef

55.

Summ O, Charbit AR, Andreou AP, Goadsby PJ (2010) Modulation of nocioceptive transmission with calcitonin gene-related peptide receptor antagonists in the thalamus. Brain 133:2540–2548PubMedCrossRef

56.

Andreou AP, Holland PR, Akerman S, Summ O, Fredrick J, Goadsby PJ (2016) Transcranial magnetic stimulation and potential cortical and trigeminothalamic mechanisms in migraine. Brain 139:2002–2014PubMedPubMedCentralCrossRef

57.

Lipton RB, Dodick DW, Silberstein SD, Saper JR, Aurora SK, Pearlman SH, Fischell RE, Ruppel PL, Goadsby PJ (2010) Single-pulse transcranial magnetic stimulation for acute treatment of migraine with aura: a randomised, double-blind, parallel-group, sham-controlled trial. Lancet Neurol 9:373–380PubMedCrossRef

58.

Leão AAP (1944) Spreading depression of activity in the cerebral cortex. J Neurophysiol 7:359–390

59.

Leao AAP (1944) Pial circulation and spreading activity in the cerebral cortex. J Neurophysiol 7:391–396

60.

Bhaskar S, Saeidi K, Borhani P, Amiri H (2013) Recent progress in migraine pathophysiology: role of cortical spreading depression and magnetic resonance imaging. Eur J Neurosci 38:3540–3551PubMedCrossRef

61.

Hadjikhani N, Sanchez Del Rio M, Wu O, Schwartz D, Bakker D, Fischl B, Kwong KK, Cutrer FM, Rosen BR, Tootell RB, Sorensen AG, Moskowitz MA (2001) Mechanisms of migraine aura revealed by functional MRI in human visual cortex. Proc Natl Acad Sci USA 98:4687–4692PubMedPubMedCentralCrossRef

62.

Bolay H, Reuter U, Dunn AK, Huang Z, Boas DA, Moskowitz MA (2002) Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model. Nat Med 8:136–142PubMedCrossRef

63.

Zhang X, Levy D, Kainz V, Noseda R, Jakubowski M, Burstein R (2011) Activation of central trigeminovascular neurons by cortical spreading depression. Ann Neurol 69:855–865PubMedPubMedCentralCrossRef

64.

Sprenger T, Borsook D (2012) Migraine changes the brain: neuroimaging makes its mark. Curr Opin Neurol 25:252–262PubMedPubMedCentralCrossRef

65.

Chong CD, Schwedt TJ, Dodick DW (2016) Migraine: what imaging reveals. Curr Neurol Neurosci Rep 16:64PubMedCrossRef

66.

Coppola G, Di Lorenzo C, Schoenen J, Pierelli F (2013) Habituation and sensitization in primary headaches. J Headache Pain 14:65PubMedPubMedCentralCrossRef

67.

Ambrosini A, Rossi P, De Pasqua V, Pierelli F, Schoenen J (2003) Lack of habituation causes high intensity dependence of auditory evoked cortical potentials in migraine. Brain 126:2009–2015PubMedCrossRef

68.

Afra J, Cecchini AP, De Pasqua V, Albert A, Schoenen J (1998) Visual evoked potentials during long periods of pattern-reversal stimulation in migraine. Brain 121(Pt 2):233–241PubMedCrossRef

69.

Schoenen J (2006) Neurophysiological features of the migrainous brain. Neurol Sci 27(suppl 2):S77–S81PubMedCrossRef

70.

Gasparini CF, Smith RA, Griffiths LR (2016) Genetic insights into migraine and glutamate: a protagonist driving the headache. J Neurol Sci 367:258–268PubMedCrossRef

71.

Freilinger T, Anttila V, de Vries B, Malik R, Kallela M, Terwindt GM, Pozo-Rosich P, Winsvold B, Nyholt DR, van Oosterhout WPJ, Artto V, Todt U, Hamalainen E, Fernandez-Morales J, Louter MA, Kaunisto MA, Schoenen J, Raitakari O, Lehtimaki T, Vila-Pueyo M, Gobel H, Wichmann E, Sintas C, Uitterlinden AG, Hofman A, Rivadeneira F, Heinze A, Tronvik E, van Duijn CM, Kaprio J, Cormand B, Wessman M, Frants RR, Meitinger T, Muller-Myhsok B, Zwart J-A, Farkkila M, Macaya A, Ferrari MD, Kubisch C, Palotie A, Dichgans M, van den Maagdenberg AMJM (2012) Genome-wide association analysis identifies susceptibility loci for migraine without aura. Nat Genet 44:777–782PubMedPubMedCentralCrossRef

72.

Humphrey PP, Feniuk W, Perren MJ, Beresford IJ, Skingle M, Whalley ET (1990) Serotonin and migraine. Ann N Y Acad Sci 600:587–598 (discussion 598–600) PubMedCrossRef

73.

Goadsby PJ, Sprenger T (2010) Current practice and future directions in the prevention and acute management of migraine. Lancet Neurol 9:285–298PubMedCrossRef

74.

Ferrari MD, Goadsby PJ, Roon KI, Lipton RB (2002) Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia 22:633–658PubMedCrossRef

75.

Ho TW, Ferrari MD, Dodick DW, Galet V, Kost J, Fan X, Leibensperger H, Froman S, Assaid C, Lines C, Koppen H, Winner PK (2008) Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet 372:2115–2123PubMedCrossRef

76.

Hewitt DJ, Aurora SK, Dodick DW, Goadsby PJ, Ge YJ, Bachman R, Taraborelli D, Fan X, Assaid C, Lines C, Ho TW (2011) Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine. Cephalalgia 31:712–722PubMedCrossRef

77.

Olesen J, Diener HC, Husstedt IW, Goadsby PJ, Hall D, Meier U, Pollentier S, Lesko LM, Group BBCPoCS (2004) Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med 350:1104–1110PubMedCrossRef

78.

Marcus R, Goadsby PJ, Dodick D, Stock D, Manos G, Fischer TZ (2014) BMS-927711 for the acute treatment of migraine: a double-blind, randomized, placebo controlled, dose-ranging trial. Cephalalgia 34:114–125PubMedCrossRef

79.

Diener HC, Barbanti P, Dahlof C, Reuter U, Habeck J, Podhorna J (2011) BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: results from a phase II study. Cephalalgia 31:573–584PubMedCrossRef

80.

Voss T, Lipton RB, Dodick DW, Dupre N, Ge JY, Bachman R, Assaid C, Aurora SK, Michelson D (2016) A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine. Cephalalgia 36:887–898PubMedCrossRef

81.

Nelson DL, Phebus LA, Johnson KW, Wainscott DB, Cohen ML, Calligaro DO, Xu YC (2010) Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan. Cephalalgia 30:1159–1169PubMedCrossRef

82.

Goadsby PJ, Classey JD (2003) Evidence for serotonin (5-HT)1B, 5-HT1D and 5-HT1F receptor inhibitory effects on trigeminal neurons with craniovascular input. Neuroscience 122:491–498PubMedCrossRef

83.

Vila-Pueyo M, Strother L, Page K, Loaraine H, Kovalchin J, Goadsby PJ, Holland PR (2016) Lasmiditan inhibits trigeminovascular nociceptive transmission. Cephalalgia 36:152

84.

Ferrari MD, Farkkila M, Reuter U, Pilgrim A, Davis C, Krauss M, Diener HC, European COLI (2010) Acute treatment of migraine with the selective 5-HT1F receptor agonist lasmiditan—a randomised proof-of-concept trial. Cephalalgia 30:1170–1178PubMedCrossRef

85.

Farkkila M, Diener HC, Geraud G, Lainez M, Schoenen J, Harner N, Pilgrim A, Reuter U, Group CM-s (2012) Efficacy and tolerability of lasmiditan, an oral 5-HT(1F) receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study. Lancet Neurol 11:405–413PubMedCrossRef

86.

Diener HC, Charles A, Goadsby PJ, Holle D (2015) New therapeutic approaches for the prevention and treatment of migraine. Lancet Neurol 14:1010–1022PubMedCrossRef

87.

Sang CN, Ramadan NM, Wallihan RG, Chappell AS, Freitag FG, Smith TR, Silberstein SD, Johnson KW, Phebus LA, Bleakman D, Ornstein PL, Arnold B, Tepper SJ, Vandenhende F (2004) LY293558, a novel AMPA/GluR5 antagonist, is efficacious and well-tolerated in acute migraine. Cephalalgia 24:596–602PubMedCrossRef

88.

Waung MW, Akerman S, Wakefield M, Keywood C, Goadsby PJ (2016) Metabotropic glutamate receptor 5: a target for migraine therapy. Ann Clin Transl Neurol 3:560–571PubMedPubMedCentralCrossRef

89.

Gomez-Mancilla B, Brand R, Jurgens TP, Gobel H, Sommer C, Straube A, Evers S, Sommer M, Campos V, Kalkman HO, Hariry S, Pezous N, Johns D, Diener HC, Group BGGS (2014) Randomized, multicenter trial to assess the efficacy, safety and tolerability of a single dose of a novel AMPA receptor antagonist BGG492 for the treatment of acute migraine attacks. Cephalalgia 34:103–113PubMedCrossRef

90.

Afridi SK, Giffin NJ, Kaube H, Goadsby PJ (2013) A randomized controlled trial of intranasal ketamine in migraine with prolonged aura. Neurology 80:642–647PubMedCrossRef

91.

Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF (2007) Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 68:343–349PubMedCrossRef

92.

Dodick DW, Goadsby PJ, Silberstein SD, Lipton RB, Olesen J, Ashina M, Wilks K, Kudrow D, Kroll R, Kohrman B, Bargar R, Hirman J, Smith J, Investigators ALDs (2014) Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial. Lancet Neurol 13:1100–1107PubMedCrossRef

93.

Dodick DW, Goadsby PJ, Spierings EL, Scherer JC, Sweeney SP, Grayzel DS (2014) Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Neurol 13:885–892PubMedCrossRef

94.

Oakes TZQ, Ferguson M, SklJarevski V, Martinez JM, Johnson KW et al (2016) Efficacy and safety of LY2951742 in a randomized double-blind, placebo-controlled, dose-ranging study in patients with migraine. Headache 46(Suppl 1):68

95.

Bigal ME, Dodick DW, Rapoport AM, Silberstein SD, Ma Y, Yang R, Loupe PS, Burstein R, Newman LC, Lipton RB (2015) Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol 14:1081–1090PubMedCrossRef

96.

Sun H, Dodick DW, Silberstein S, Goadsby PJ, Reuter U, Ashina M, Saper J, Cady R, Chon Y, Dietrich J, Lenz R (2016) Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol 15:382–390PubMedCrossRef

97.

Bigal ME, Edvinsson L, Rapoport AM, Lipton RB, Spierings EL, Diener HC, Burstein R, Loupe PS, Ma Y, Yang R, Silberstein SD (2015) Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol 14:1091–1100PubMedCrossRef

98.

Smith J, Dodick D, Goadsby PJ, Silberstein SD, Lipton RB, Chakava G, O’Brien T, Hill R, Krause RA, Bonner J, Koltun W, Hirman J (2016) Randomized, double-blind, placebo-controlled trial of ALD403, an anti-CGRP antibody in the prevention of chronic migraine. Headache 56:1391CrossRef

99.

Goldstein DJ, Offen WW, Klein EG, Phebus LA, Hipskind P, Johnson KW, Ryan RE Jr (2001) Lanepitant, an NK-1 antagonist, in migraine prevention. Cephalalgia 21:102–106PubMedCrossRef

100.

Chabi A, Zhang Y, Jackson S, Cady R, Lines C, Herring WJ, Connor KM, Michelson D (2015) Randomized controlled trial of the orexin receptor antagonist filorexant for migraine prophylaxis. Cephalalgia 35:379–388PubMedCrossRef

101.

Lipton RBGP, Cady RK, Aurora SK, Grosberg BM, Freitag FG et al (2009) PRISM study: occipital nerve stimulation for treatment refractory migraine. Cephalalgia 29(Suppl 1):30

102.

Saper JR, Dodick DW, Silberstein SD, McCarville S, Sun M, Goadsby PJ, Investigators O (2011) Occipital nerve stimulation for the treatment of intractable chronic migraine headache: ONSTIM feasibility study. Cephalalgia 31:271–285PubMedPubMedCentralCrossRef

103.

Silberstein SD, Dodick DW, Saper J, Huh B, Slavin KV, Sharan A, Reed K, Narouze S, Mogilner A, Goldstein J, Trentman T, Vaisman J, Ordia J, Weber P, Deer T, Levy R, Diaz RL, Washburn SN, Mekhail N (2012) Safety and efficacy of peripheral nerve stimulation of the occipital nerves for the management of chronic migraine: results from a randomized, multicenter, double-blinded, controlled study. Cephalalgia 32:1165–1179PubMedCrossRef

104.

Dodick DW, Silberstein SD, Reed KL, Deer TR, Slavin KV, Huh B, Sharan AD, Narouze S, Mogilner AY, Trentman TL, Ordia J, Vaisman J, Goldstein J, Mekhail N (2015) Safety and efficacy of peripheral nerve stimulation of the occipital nerves for the management of chronic migraine: long-term results from a randomized, multicenter, double-blinded, controlled study. Cephalalgia 35:344–358PubMedCrossRef

105.

May A, Goadsby PJ (1999) The trigeminovascular system in humans: pathophysiologic implications for primary headache syndromes of the neural influences on the cerebral circulation. J Cereb Blood Flow Metab 19:115–127PubMedCrossRef

106.

Puledda F, Goadsby PJ (2016) Current approaches to neuromodulation in primary headaches: focus on vagal nerve and sphenopalatine ganglion stimulation. Curr Pain Headache Rep 20:47PubMedPubMedCentralCrossRef

107.

Maizels M, Geiger AM (1999) Intranasal lidocaine for migraine: a randomized trial and open-label follow-up. Headache 39:543–551PubMedCrossRef

108.

Cady R, Saper J, Dexter K, Manley HR (2015) A double-blind, placebo-controlled study of repetitive transnasal sphenopalatine ganglion blockade with tx360((R)) as acute treatment for chronic migraine. Headache 55:101–116PubMedCrossRef

109.

Tepper SJ, Rezai A, Narouze S, Steiner C, Mohajer P, Ansarinia M (2009) Acute treatment of intractable migraine with sphenopalatine ganglion electrical stimulation. Headache 49:983–989PubMedCrossRef

110.

Cady RK, Saper J, Dexter K, Cady RJ, Manley HR (2015) Long-term efficacy of a double-blind, placebo-controlled, randomized study for repetitive sphenopalatine blockade with bupivacaine vs. saline with the Tx360 device for treatment of chronic migraine. Headache 55:529–542PubMedCrossRef

111.

Schoenen J, Vandersmissen B, Jeangette S, Herroelen L, Vandenheede M, Gerard P, Magis D (2013) Migraine prevention with a supraorbital transcutaneous stimulator: a randomized controlled trial. Neurology 80:697–704PubMedCrossRef

112.

Magis D, Sava S, d’Elia TS, Baschi R, Schoenen J (2013) Safety and patients’ satisfaction of transcutaneous supraorbital neurostimulation (tSNS) with the Cefaly(R) device in headache treatment: a survey of 2,313 headache sufferers in the general population. J Headache Pain 14:95PubMedPubMedCentralCrossRef

113.

Barbanti P, Grazzi L, Egeo G, Padovan AM, Liebler E, Bussone G (2015) Non-invasive vagus nerve stimulation for acute treatment of high-frequency and chronic migraine: an open-label study. J Headache Pain 16:61PubMedPubMedCentralCrossRef

114.

Goadsby PJ, Grosberg BM, Mauskop A, Cady R (2014) Effect of non-invasive vagus nerve stimulation on acute migraine: an open label pilot study. Cephalalgia 34:986–993PubMedCrossRef

115.

Moscato D, Moscato FR, Liebler EJ (2014) Efficacy of noninvasive vagus nerve stimulation (nVNS) in the treatment of acute migraine attacks. Headache 44:1418

116.

Silberstein SD, Calhoun AH, Lipton RB, Grosberg BM, Cady RK, Dorlas S, Simmons KA, Mullin C, Liebler EJ, Goadsby PJ, Saper JR, Group ES (2016) Chronic migraine headache prevention with noninvasive vagus nerve stimulation: The EVENT study. Neurology 87:529–538PubMedPubMedCentralCrossRef

117.

Grazzi L, Egeo G, Calhoun AH, McClure CK, Liebler E, Barbanti P (2016) Non-invasive Vagus Nerve Stimulation (nVNS) as mini-prophylaxis for menstrual/menstrually related migraine: an open-label study. J Headache Pain 17:91PubMedPubMedCentralCrossRef

118.

Lipton RB, Pearlman SH (2010) Transcranial magnetic simulation in the treatment of migraine. Neurotherapeutics 7:204–212PubMedPubMedCentralCrossRef

119.

Bhola R, Kinsella E, Giffin N, Lipscombe S, Ahmed F, Weatherall M, Goadsby PJ (2015) Single-pulse transcranial magnetic stimulation (sTMS) for the acute treatment of migraine: evaluation of outcome data for the UK post market pilot program. J Headache Pain 16:535PubMedCrossRef

120.

Antal A, Kriener N, Lang N, Boros K, Paulus W (2011) Cathodal transcranial direct current stimulation of the visual cortex in the prophylactic treatment of migraine. Cephalalgia 31:820–828PubMedCrossRef

121.

Vigano A, D’Elia TS, Sava SL, Auve M, De Pasqua V, Colosimo A, Di Piero V, Schoenen J, Magis D (2013) Transcranial direct current stimulation (tDCS) of the visual cortex: a proof-of-concept study based on interictal electrophysiological abnormalities in migraine. J Headache Pain 14:23PubMedPubMedCentralCrossRef

Title: An update on migraine: current understanding and future directions
Authors: Francesca Puledda
Roberta Messina
Peter J. Goadsby
Publication date: 01-09-2017
Publisher: Springer Berlin Heidelberg
Published in: Journal of Neurology / Issue 9/2017
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-017-8434-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

An update on migraine: current understanding and future directions

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 9/2017

Magnetic resonance imaging of leg muscles in patients with myotonic dystrophies

Michael Kremer (1907–1988)

Genetics of disease severity in multiple sclerosis, Alzheimer’s disease, and Huntington’s disease: rejuvenating genome-wide association studies

Early trigeminal nerve involvement in Listeria monocytogenes rhombencephalitis: case series and systematic review

Simultaneous EEG–PET–fMRI measurements in disorders of consciousness: an exploratory study on diagnosis and prognosis

Midlife work-related stress is associated with late-life cognition